AAAAAA
Results: 1-25/146
Authors:
MARKMAN M
Citation: M. Markman, WHY SHOULD CANCER-PATIENTS PARTICIPATE IN CLINICAL-TRIALS, Cleveland Clinic journal of medicine, 65(9), 1998, pp. 497-499
Authors:
MARKMAN M
Citation: M. Markman, THE CRUEL CANCER CURE HYPE, Cleveland Clinic journal of medicine, 65(7), 1998, pp. 386-387
Authors:
MARKMAN M
Citation: M. Markman, CANCER INFORMATION AND THE INTERNET - BENEFITS AND RISKS, Cleveland Clinic journal of medicine, 65(5), 1998, pp. 274-276
Authors:
MARKMAN M
Citation: M. Markman, THE HIGH COST OF TERMINAL CARE - BALANCING CONFLICTING GOALS, Cleveland Clinic journal of medicine, 65(4), 1998, pp. 219-221
Authors:
MARKMAN M
Citation: M. Markman, CANCER AND THE MIND - SEPARATING FACT FROM FICTION, Cleveland Clinic journal of medicine, 65(2), 1998, pp. 107-109
Authors:
MARKMAN M
Citation: M. Markman, SALVAGE THERAPY FOR OVARIAN-CANCER, Oncology, 12(6), 1998, pp. 851-851
Authors:
MARKMAN M
Citation: M. Markman, SHOULD COST BE CONSIDERED IN THE OVERALL EVALUATION OF PHASE-II CLINICAL-TRIALS OF NEW ANTINEOPLASTIC THERAPIES - RESPONSE, Cancer investigation, 16(2), 1998, pp. 142-143
Authors:
MARKMAN M
BRADY MF
SPIRTOS NM
HANJANI P
RUBIN SC
Citation: M. Markman et al., PHASE-II TRIAL OF INTRAPERITONEAL PACLITAXEL IN CARCINOMA OF THE OVARY, TUBE, AND PERITONEUM - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY, Journal of clinical oncology, 16(8), 1998, pp. 2620-2624
Authors:
MARKMAN M
ROSE PG
JONES E
HOROWITZ IR
KENNEDY A
WEBSTER K
BELINSON J
FUSCO N
FLUELLEN L
KULP B
PETERSON G
MCGUIRE WP
Citation: M. Markman et al., 96-HOUR INFUSIONAL PACLITAXEL AS SALVAGE THERAPY OF OVARIAN-CANCER PATIENTS PREVIOUSLY FAILING TREATMENT WITH 3-HOUR OR 24-HOUR PACLITAXEL INFUSION REGIMENS, Journal of clinical oncology, 16(5), 1998, pp. 1849-1851
Authors:
PEREZ EA
HESKETH P
SANDBACH J
REEVES J
CHAWLA S
MARKMAN M
HAINSWORTH J
BUSHNELL W
FRIEDMAN C
Citation: Ea. Perez et al., COMPARISON OF SINGLE-DOSE ORAL GRANISETRON VERSUS INTRAVENOUS ONDANSETRON IN THE PREVENTION OF NAUSEA AND VOMITING INDUCED BY MODERATELY EMETOGENIC CHEMOTHERAPY - A MULTICENTER, DOUBLE-BLIND, RANDOMIZED PARALLEL STUDY, Journal of clinical oncology, 16(2), 1998, pp. 754-760
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., PACLITAXEL ADMINISTRATION TO GYNECOLOGIC CANCER-PATIENTS WITH MAJOR CARDIAC RISK-FACTORS, Journal of clinical oncology, 16(11), 1998, pp. 3483-3485
Authors:
ROOSE J
KORVER W
OVING E
WILSON A
WAGENAAR G
MARKMAN M
LAMERS W
CLEVERS H
Citation: J. Roose et al., HIGH EXPRESSION OF THE HMG BOX FACTOR SOX-13 IN ARTERIAL-WALLS DURINGEMBRYONIC-DEVELOPMENT, Nucleic acids research, 26(2), 1998, pp. 469-476
Authors:
KORINEK V
BARKER N
WILLERT K
MOLENAAR M
ROOSE J
WAGENAAR G
MARKMAN M
LAMERS W
DESTREE O
CLEVERS H
Citation: V. Korinek et al., 2 MEMBERS OF THE TCF FAMILY IMPLICATED IN WNT BETA-CATENIN SIGNALING DURING EMBRYOGENESIS IN THE MOUSE/, Molecular and cellular biology, 18(3), 1998, pp. 1248-1256
Authors:
MARKMAN M
Citation: M. Markman, A PHASE-2 STUDY OF WEEKLY HIGH-DOSE 5-FLUOROURACIL AND LEUCOVORIN PLUS BIWEEKLY ALTERNATING DOXORUBICIN AND CISPLATIN FOR ADVANCED GASTRIC-CANCER, Journal of cancer research and clinical oncology, 124(7), 1998, pp. 353-353
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., EVIDENCE THAT A TREATMENT-FREE INTERVAL OF LESS-THAN 6 MONTHS DOES NOT EQUATE WITH CLINICALLY DEFINED PLATINUM RESISTANCE IN OVARIAN-CANCEROR PRIMARY PERITONEAL CARCINOMA, Journal of cancer research and clinical oncology, 124(6), 1998, pp. 326-328
Authors:
MARKMAN M
Citation: M. Markman, PACLITAXEL AS A COMPONENT OF INITIAL CHEMOTHERAPY OF ADVANCED OVARIAN-CANCER - IS THE CONTROVERSY RESOLVED, Journal of cancer research and clinical oncology, 124(1), 1998, pp. 1-3
Authors:
XU Y
SHEN ZZ
WIPER DW
WU MZ
MORTON RE
ELSON P
KENNEDY AW
BELINSON J
MARKMAN M
CASEY G
Citation: Y. Xu et al., LYSOPHOSPHATIDIC ACID AS A POTENTIAL BIOMARKER FOR OVARIAN AND OTHER GYNECOLOGIC CANCERS, JAMA, the journal of the American Medical Association, 280(8), 1998, pp. 719-723
Authors:
MARKMAN M
Citation: M. Markman, AMIFOSTINE IN REDUCING CISPLATIN TOXICITY, Seminars in oncology, 25(5), 1998, pp. 522-524
Authors:
MARKMAN M
Citation: M. Markman, INTRAPERITONEAL THERAPY OF OVARIAN-CANCER, Seminars in oncology, 25(3), 1998, pp. 356-360
Authors:
MARKMAN M
KENNEDY A
WEBSTER K
KULP B
PETERSON G
BELINSON J
Citation: M. Markman et al., LOW-DOSE ORAL GRANISETRON (1 MG) PLUS INTRAVENOUS DEXAMETHASONE - EFFICACY IN GYNECOLOGIC CANCER-PATIENTS RECEIVING CARBOPLATIN-BASED CHEMOTHERAPY, Gynecologic oncology (Print), 71(1), 1998, pp. 113-115
Authors:
MARKMAN M
KENNEDY A
SUTTON G
HURTEAU J
WEBSTER K
PETERSON G
KULP B
BELINSON J
Citation: M. Markman et al., PHASE-2 TRIAL OF SINGLE-AGENT IFOSFAMIDE MESNA IN PATIENTS WITH PLATINUM/PACLITAXEL REFRACTORY OVARIAN-CANCER WHO HAVE NOT PREVIOUSLY BEEN TREATED WITH AN ALKYLATING AGENT/, Gynecologic oncology (Print), 70(2), 1998, pp. 272-274
Authors:
MARKMAN M
LICHTMAN SM
HOMESLEY H
KENNEDY A
WEBSTER K
ERNST S
OMURA G
BELINSON J
Citation: M. Markman et al., PHASE-2 TRIAL OF MODERATELY HIGH-DOSE SINGLE-AGENT MITOXANTRONE IN PLATINUM AND PACLITAXEL-REFRACTORY OVARIAN-CANCER, Gynecologic oncology (Print), 70(1), 1998, pp. 123-126
Authors:
MARKMAN M
BLESSING JA
MOORE D
BALL H
LENTZ SS
Citation: M. Markman et al., ALTRETAMINE (HEXAMETHYLMELAMINE) IN PLATINUM-RESISTANT AND PLATINUM-REFRACTORY OVARIAN-CANCER - A GYNECOLOGIC-ONCOLOGY-GROUP PHASE-II TRIAL, Gynecologic oncology (Print), 69(3), 1998, pp. 226-229
Authors:
MARKMAN M
Citation: M. Markman, RECURRENCE WITHIN 6 MONTHS OF PLATINUM THERAPY - AN ADEQUATE DEFINITION OF PLATINUM-REFRACTORY OVARIAN-CANCER, Gynecologic oncology, 69(2), 1998, pp. 91-92
Authors:
MARKMAN M
Citation: M. Markman, PROGNOSTIC FACTORS IN SALVAGE THERAPY OF OVARIAN-CANCER, Annals of oncology, 8(10), 1997, pp. 937-938